摘要
目的:探讨内皮素-1(Endothelin-1,ET-1)与前列腺癌(PCa)的关系及其临床意义。方法:应用放射免疫分析法对31例PCa患者血浆中ET-1水平进行检测,其中新发PCa且对内分泌治疗敏感者(non-HRPC)23例,激素难治性PCa(HRPC)8例;以26例良性前列腺增生(BPH)患者作为对照,并作对比分析。结果:血浆ET-1水平在BPH组、未经治疗的PCa组及对雄激素治疗不敏感PCa组3组之间相互比较,差异均无显著性(P>0.05);在高、中分化PCa中血浆ET-1水平差异无显著性(P>0.05),但显著高于低分化PCa(P<0.05);在骨转移癌和非骨转移癌之间差异无显著性;在PSA各分组之间的ET-1水平,差异无显著性(P>0.05)。结论:血浆ET-1水平检测,未能反映PCa的发生发展和预后。
Objective： To investigate plasma endothelin-1 （ET-1） level in patients with prostate cancers and its clinical significance. Methods： Plasma ET-1 level was measured by radioimmunoassay in 31 patients of prostate cancer （23 with non-HRPC, 8 with HRPC） and 26 patients of BPH. Results ： Compared with each other of the ET-1 level, there were no significant difference among the BPH group, non-HRPC group and HRPC group. No significant difference was found either between bone metastasis（BM） and non- BM, between high and middling differentiation prostate cancer group, as well as in different PSA level groups（ P 〉 0.05 ）. But the ET-1 level in low differentiation prostate cancer was notably lower than those of the high and middle respectively （ P 〈 0. 05 ）. Conclusion ： To detect plasma endotbelin-1 （ ET-1 ） level is not a useful method to evaluate the development and the prognosis of prostate cancer.
出处
《中华男科学杂志》
CAS
CSCD
2006年第4期315-317,322,共4页
National Journal of Andrology
基金
国家杰出青年基金(30225046)
关键词
前列腺癌
良性前列腺增生
内皮素-1
prostate cancer
benign prostatic hyperplasia
endothelin-1
